Skip to content
Sparsentan
Filspari (sparsentan) is a small molecule pharmaceutical. Sparsentan was first approved as Filspari on 2023-02-17. It is used to treat proteinuria in the USA. The pharmaceutical is active against type-1 angiotensin II receptor and endothelin-1 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Filspari
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sparsentan
Tradename
Company
Number
Date
Products
FILSPARITravere TherapeuticsN-216403 RX2023-02-17
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
filspariNew Drug Application2023-02-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
proteinuriaHP_0000093D011507R80
Agency Specific
FDA
EMA
Expiration
Code
SPARSENTAN, FILSPARI, TRAVERE
2030-02-17ODE-389
2028-02-17NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Sparsentan, Filspari, Travere
99934612030-03-29U-3269
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Iga glomerulonephritisD005922EFO_0004194—21——3
Focal segmental glomerulosclerosisD005923EFO_0004236—21——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10—2———2
Kidney diseasesD007674EFO_0003086N08—2———2
GlomerulonephritisD005921N05—1———1
Immune system diseasesD007154D89.9—1———1
Autoimmune diseasesD001327EFO_0000540M30-M36—1———1
Hereditary nephritisD009394EFO_0004128Q87.81—1———1
Lipoid nephrosisD009402EFO_1001020N04—1———1
Cardiovascular diseasesD002318EFO_0000319I98—1———1
Anti-neutrophil cytoplasmic antibody-associated vasculitisD056648I77.82—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSPARSENTAN
INNsparsentan
Description
Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. Sparsentan is an endothelin and angiotensin II receptor antagonist.
Classification
Small molecule
Drug classendothelin receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
Identifiers
PDB—
CAS-ID254740-64-2
RxCUI—
ChEMBL IDCHEMBL539423
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID9242RO5URM (ChemIDplus, GSRS)
Target
Agency Approved
AGTR1
AGTR1
EDNRA
EDNRA
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
185
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Q8TBK4
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Filspari - Travere Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 117 documents
View more details
Safety
Black-box Warning
Black-box warning for: Filspari
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details